Angion Biomedica Corp (NasdaqGS: ANGN)
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Angion Biomedica Corp (“the Company”) (NasdaqGS: ANGN) with Elicio Therapeutics pursuant to which Angion shareholders are expected to own approximately 34.5% of the newly combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857, or fill out the form on this page.